Acute pulmonary embolism (PE) is an extreme form of venous thromboembolism and is associated with significant morbidity and mortality 1, 2 . Various biomarkers, in particular d-dimers, have been recommended to be used to stratify the risk of patients who have symptoms of acute PE, so that unnecessary invasive diagnostic radiological studies can be minimised in low-risk patients 3 .
Evidence suggests that thrombocytosis is associated with an increased risk of in vitro thrombotic tendency and clinical thromboembolic events including acute PE 2, 4, 5 . On the other hand, thrombocytopaenia or an abnormal coagulation profile is associated with an increased risk of bleeding and possibly a lower risk of venous thromboembolism. Thrombocytopaenia or coagulopathy is not rare in hospitalised patients with sepsis or pneumonia who may also have symptoms such as chest pain, shortness of pain, hypotension and hypoxaemia suggestive of acute PE 6, 7 . Theoretically, the presence of coagulopathy should be more suggestive of a septic process, such as pneumonia, rather than acute PE. As such, the presence of coagulopathy may be useful to assist clinical decisionmaking about the risk of acute PE in patients who have symptoms suggestive of acute PE.
We hypothesised that significant acquired coagulo pathy is more common in patients with pneumonia or other pulmonary pathologies than in patients with acute PE. In this retrospective cohort study, we assessed whether the presence of acquired coagulopathy can be useful to exclude acute PE in patients who have symptoms suggestive of acute PE.
METHODS
After obtaining Royal Perth Hospital Ethics Committee approval (075/2012), clinical, laboratory and radiology data of consecutive patients who had symptoms suggestive of acute PE requiring computed tomography pulmonary angiography (CTPA) to SUMMARy Thrombocytopaenia or an abnormal coagulation profile is not rare in hospitalised patients who have symptoms consistent with acute pulmonary embolism (PE). Theoretically, coagulopathy is more likely to occur in patients with pneumonia than acute PE. This study aimed to assess whether the presence of coagulopathy could be used to exclude acute PE in patients with symptoms and signs consistent with acute PE. In this study, a significant coagulopathy was defined as a platelet count <100 × 10 9 /l, an international normalised ratio >1.5, or activated partial thromboplastin time >50 seconds. Patients treated with systemic anticoagulants prior to computed tomography pulmonary angiography were excluded. Of the 986 consecutive patients who required computed tomography pulmonary angiography to exclude acute PE over a four-month period in five hospitals in Western Australia, acute PE was confirmed in 149 patients (15.1%). The incidence of coagulopathy was not significantly different between those with and without acute PE (4 vs 7%, respectively; P=0.161) and between those with and without pneumonia (8 vs 7%, respectively; P=0.505). Positive and negative likelihood ratios of coagulopathy in differentiating acute PE or pneumonia were both unsatisfactory. As a continuous predictor, platelet counts, international normalised ratio, activated partial thromboplastin time and plasma fibrinogen concentrations were also not useful in differentiating between acute PE and other pulmonary pathologies (areas under the receiver operating characteristic curve were all close to 0.5). In conclusion, the presence of significant acquired coagulopathy cannot be used to suggest pneumonia or exclude symptomatic acute PE when the prevalence or pre-test probability of acute PE is not low. exclude acute PE over a four-month period (January to April 2012) in five metropolitan hospitals (Royal Perth Hospital, Sir Charles Gairdner Hospital, Fremantle Hospital, Swan District Hospital and Rockingham Hospital) in Western Australia were obtained. Patients who had undergone CTPA for reasons other than to diagnose or exclude acute PE, who were treated with warfarin or unfractionated heparin for more than 24 hours prior to CTPA and those without any laboratory blood tests performed before CTPA were excluded from this study. Only blood tests performed within the 24 hours prior to CTPA were analysed for their association with risk of acute PE or pneumonia.
In this study, significant acquired coagulopathy was defined as a platelet count <100×10 9 /l, an international normalised ratio (INR) >1.5, or activated partial thromboplastin time (aPTT) >50 seconds. The primary outcome of this study was the incidence of coagulopathy in patients who had acute PE confirmed by CTPA, and the diagnostic ability of coagulopathy in differentiating between acute PE and other respiratory pathologies in patients who had clinical symptoms and signs suggestive of acute PE requiring CTPA to exclude acute PE. Because d-dimers have been recommended in the diagnostic work-up of patients who have symptoms suggestive of acute PE, we also assessed the diagnostic ability of d-dimers in diagnosing acute PE in this study. A ddimers concentration >0.4 mg/l was defined as a positive d-dimers test by the laboratory. Radiologists' reports of the CTPA were considered as confirmation of the diagnosis, which might include PE, pneumonia, interstitial lung disease or other diagnosis, and all data were confirmed by the two investigators of this study before analysis.
Statistical analysis
Assuming the prevalence of acute PE for hospitalised patients who had symptoms suggestive of PE was about 10% and the incidence of significant acquired coagulopathy was 15% among those without acute PE, a sample size of 936 patients would have a power of 90% to exclude a relative risk of three in the association between coagulopathy and acute PE. A total sample size of 1000 was planned to allow for 'lost to follow-up'.
Differences in categorical and continuous variables between patients with acute PE and those without acute PE were analysed by chisquare and ttest, respectively. In this study, mortality of the patients was censored on 1 September 2012. Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were used to reflect the diagnostic ability of coagulopathy and d-dimers in diagnosing acute PE and pneumonia. Because the cut-points chosen in the categorical analyses may not have been optimal, the diagnostic ability of platelet counts, INR, aPTT and fibrinogen concentrations were also assessed by the area under the receiver operating characteristic curve by considering these parameters as a continuous variable. All analyses were conducted by SPSS for Windows (version 19.0, 2011, IBM, USA) and Confidence Interval Analysis (version 2.0.0, 2000, BMJ, UK) and a P value <0.05 was taken as significant.
RESUlTS
Of the 986 patients included in the study, acute PE was confirmed in 149 patients (15%; Figure 1 ). The age, sex and presenting symptoms were not significantly different between those who had acute PE and those 35 patients (3%) were excluded because of inability to complete the CTPA, no blood tests within 24 hours or treated with systemic anticoagulation for more than 24 hours prior to the CTPA 149 patients (15%) with acute PE on CTPA (48 with unilateral PE, 91 with bilateral PE, 10 with saddle PE)-19 patients died as on 1 September 2012 (13%) -173 (18%) with pneumonia -203 (21%) with emphysema/bronchitis -51 (5%) with atelectasis or collapse of lung segments -29 (3%) with pleural effusion -12 (1%) with cardiogenic or non-cardiogenic pulmonary oedema -9 with bronchiectasis -8 with nodular lesion in the lungs or cancer -4 with interstitial lung disease -2 with aortic aneurysm or dissection -346 with others diagnosis or no abnormality detected (35%) 986 patients (97%) included in the study 1021 consecutive patients referred for computed tomography pulmonary angiography (CTPA) to exclude acute pulmonary embolism (PE) between January and April 2012 in five metropolitan hospitals in Western Australia who did not. The d-dimers concentrations (3.6 vs 1.5 mg/l, P=0.001) and the proportion of patients with a positive d-dimers test (99 vs 90%, P=0.019) were significantly higher among patients who had acute PE than those without acute PE (Table 1 and Figure  2 ). A total of 67 patients (6.8%) had some form of coagulopathy. The median platelet counts of those with thrombocytopaenia were 62×10 9 /l (interquartile range 38-83×10 9 /l). The median INR for those with an abnormal INR was 1.9 (interquartile range 1.8-2.5) and the median aPTT for those with an abnormal aPTT was 65 seconds (interquartile range 52-82). The incidence of significant coagulopathy was, however, not significantly different between patients with acute PE and those without acute PE (4 vs 7%, respectively; P=0.161).
Although the specificity and negative predictive value of coagulopathy in relation to acute PE were high, both the negative and positive likelihood ratios were not substantially different from one ( Table 2 ), suggesting that coagulopathy could not be used reliably to change the post-test probability of acute PE in patients with signs and symptoms consistent with acute PE. A positive d-dimers test had a high sensitivity and low negative likelihood ratio for acute PE, but both a positive d-dimers test and coagulopathy were not useful in diagnosing pneumonia in patients with symptoms suggestive of acute PE. As a continuous predictor, only d-dimers concentrations (area under receiver operating characteristic curve=0.76, 95% confidence interval: 0.70-0.83), but not platelet counts, INR or aPTT (areas under the receiver operating characteristic curve all close to 0.5), had a reasonably good discriminative ability to differentiate between acute PE and other pulmonary pathologies (Table 3) .
DISCUSSION
Our results showed that significant acquired coagu lopathy was not rare among hospitalised patients who presented with signs and symptoms of acute PE, but the presence of coagulopathy could not be reliably used to exclude acute PE or suggest pneumonia. We also showed that d-dimers concentrations had a reasonable ability to differentiate acute PE and other pulmonary pathologies, but a positive standard d-dimers test was extremely common among hospitalised patients, even without acute PE. These results have some clinical significance and require careful consideration.
First, thrombocytopaenia or an abnormal coagulation profile in INR or aPTT have traditionally been associated with an increased risk of bleeding, hence it would appear counter-intuitive to observe that patients with significant acquired coagulopathy could present with venous thromboembolism including acute PE. However, there is increasing evidence that patients with an abnormal coagulation profile can have increased risk of both bleeding and thrombotic complications, including patients with liver cirrhosis 8 . Recent evidence suggested that a prolonged INR and aPTT do not exclude a deficiency in anticoagu lants such as protein C or an increased thrombotic tendency 9 . Furthermore, venous thromboembolism can also be contributed to by other factors such as venous stasis and endothelial injury 10 . Both of these factors are prevalent in many hospitalised patients, including those with coagulopathy from infection or trauma.
Second, our recent observational study showed that omission of early thromboprophylaxis in patients who were considered to have contraindications to pharmacological thromboprophylaxis was associated with an increased risk of mortality in critically ill patients 11 . Although this result could be explained by residual confounding, it is also possible that an increased risk of venous thromboembolism might have, in part, contributed to the higher risk of mortality for those with coagulopathy and omission of early thromboprophylaxis 12 . Further analysis of our previous study on in-vitro thrombotic tendency of critically ill patients showed that 37% of the patients who had a raised INR or aPTT were, in fact, associated with an increased risk of in-vitro thrombotic tendency as measured by thromboelastography 5 . Whether pharmacological thromboprophylaxis should be routinely used for patients who have acquired coagulopathy remains, however, uncertain. Recent evidence suggests that thromboelastography may be useful to guide thromboprophylaxis when the balance between thrombotic and bleeding risk in a patient is unpredictable 13, 14 .
Third, the utility of a biomarker can vary substantially, depending on the pre-test probability of the outcome of interest 15 . Although d-dimers concentration has been recommended to exclude venous thromboembolism including acute PE in low-risk patients 3 , our results showed that a standard positive d-dimers test is unlikely to be useful in hospitalised patients with symptoms suggestive of acute PE. This is due to the fact that most patients with pulmonary pathologies other than acute PE also had a raised d-dimers concentration (false positive rate 90%) and hence the utility of a negative d-dimers test to reduce utilisation of CTPA is low. Nevertheless, the usefulness of a higher d-dimers concentration threshold (e.g. >2 mg/l) to differentiate between acute PE and other pulmonary pathologies in hospitalised patients with symptoms suggestive of acute PE remains uncertain and this merits further investigation by a large prospective cohort study.
The last consideration is the limitations of the study. First, we have used CTPA as a gold standard in defining acute PE in this study and some patients with small subsegmental PE might have been misclassified as not having acute PE. Second, we did not have data on causes of coagulopathy in our patients. It is possible that different causes of coagulopathy may have different effects on risk of thromboembolism. Finally, the number of patients with coagulopathy (6.8%), especially those with severe coagulopathy (e.g. platelet count <50×10 9 /l, INR >2.0 and aPTT >60 seconds), was relatively small and, as such, we could not exclude a type II error in concluding that coagulopathy was not associated with a reduced risk of acute PE. The association between risk of acute PE and severe coagulopathy, stratified by either thrombocytopaenia or raised INR/aPTT, merits further investigation.
In summary, the presence of significant acquired coagulopathy cannot be used to suggest pneumonia or exclude symptomatic acute PE when the prevalence or pre-test probability of acute PE is not low. Although acute PE was associated with a higher d-dimers concentration than other pulmonary pathologies, a traditional positive d-dimers concentration (>0.4 mg/l) was not useful in excluding acute PE in hospitalised patients with symptoms suggestive of acute PE. Whether a higher threshold of d-dimers concentration can be useful for this type of patient remains uncertain and this merits further investigation.
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